Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

Cambridge Heart releases new MTWA software

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today announced the release of its redesigned Microvolt T-Wave Alternans software for its HearTwave II and CH2000 platforms.

25 Apr 2011

Canada Prime Minister announces $10 million fund for defibrillators and related training

Today Prime Minister Stephen Harper announced a $10 million plan to fund life-saving automated external defibrillators and related training in hockey arenas and community recreation centres across Canada.

22 Apr 2011

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative mitochondrial therapies, introduced its lead clinical candidate, Bendavia™, a novel compound that targets the mitochondrion, during multiple scientific sessions of the Experimental Biology 2011 meeting.

20 Apr 2011

Baxter enters definitive agreement to acquire Prism

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire privately-held Prism Pharmaceuticals, Inc., a specialty pharmaceutical company based in King of Prussia, PA. Prism Pharmaceuticals has developed and received U.S. Food and Drug Administration (FDA) approval for multiple presentations of NEXTERONE® (amiodarone HCl), an antiarrhythmic agent.

From Baxter International Inc. 18 Apr 2011

New publication on therapeutic hypothermia and temperature management

The successful use and evaluation of therapeutic hypothermia to improve survival and reduce the risk of neurological consequences following an out-of-hospital heart attack are explored in the premier issue of Therapeutic Hypothermia and Temperature Management, a new quarterly peer-reviewed journal published by Mary Ann Liebert, Inc.

8 Apr 2011

ZOLL begins shipments of new AED Plus version as per AHA, ERC Guidelines

ZOLL® Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it has begun shipments of a new version of its AED Plus that is fully compliant with the new American Heart Association and European Resuscitation Council Guidelines issued in October of 2010.

8 Apr 2011

EKG test is a poor predictor of sudden death syndrome in young athletes

The sudden death of a young athlete always prompts full media attention, most recently spurring a call for preventative screening methods, including costly electrocardiogram tests for all school-age athletes.

6 Apr 2011

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies, announced today the results of a healthy volunteers Phase I clinical study of Bendavia™, a novel compound that targets the mitochondrion to treat ischemia reperfusion injury.

4 Apr 2011

Therapeutic hypothermia is an effective treatment for young adult patients with HCM

Young adult patients with genetic heart diseases, such as hypertrophic cardiomyopathy, substantially benefitted from therapeutic hypothermia, which could further extend the role for this treatment strategy in new patient populations, according to a scientific presentation at the American College of Cardiology Scientific Sessions in New Orleans, April 1-3.

4 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Doctors who use iResus application perform better simulated cardiac arrest emergency

Doctors who used a free iPhone application provided by the UK Resuscitation Council performed significantly better in a simulated medical emergency than those who did not, according to a study in the April issue of Anaesthesia.

29 Mar 2011

Pilot study shows feasibility of heart screening for risk of SCA in children

A pilot study in healthy children and adolescents shows that it is feasible to screen for undiagnosed heart conditions that increase the risk of sudden cardiac arrest.

18 Mar 2011

Sports medicine physician suggests cardiac screening for young athletes requires augmentation of existing diagnostics to achieve greater accuracy, become cost-effective

Sports medicine physician Steve Watts says cardiac screening for young athletes is useful in preventing sudden cardiac death and suggests new diagnostics have the potential to add value and change the debate about the viability of cardiac screening for young athletes in the United States.

17 Mar 2011

Wnt1 protein can improve function of endothelial progenitor cells

Circulating through the bloodstream of every human being is a rare and powerful type of cell, one that can actually create new blood vessels to bypass blockages that cause heart attacks and peripheral artery disease.

10 Mar 2011

NSW selects ZOLL AED Plus devices for Rural Fire Service stations

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it has received an award from the Government of NSW Australia to provide 5450 AED Plus devices for installation on all Rural Fire Service stations deployed throughout the State of New South Wales.

10 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Cambridge Heart releases new MTWA software

Canada Prime Minister announces $10 million fund for defibrillators and related training

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Baxter enters definitive agreement to acquire Prism

New publication on therapeutic hypothermia and temperature management

ZOLL begins shipments of new AED Plus version as per AHA, ERC Guidelines

EKG test is a poor predictor of sudden death syndrome in young athletes

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

Therapeutic hypothermia is an effective treatment for young adult patients with HCM

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Doctors who use iResus application perform better simulated cardiac arrest emergency

Pilot study shows feasibility of heart screening for risk of SCA in children

Sports medicine physician suggests cardiac screening for young athletes requires augmentation of existing diagnostics to achieve greater accuracy, become cost-effective

Wnt1 protein can improve function of endothelial progenitor cells

NSW selects ZOLL AED Plus devices for Rural Fire Service stations

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Experts to discuss cause of sudden death on athletic playing fields

Experimental drug may help preserve neurological function in survivors of sudden cardiac arrest

New CPR method improves long-term survival rates in patients with cardiac arrest by 50%

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in